Suppr超能文献

采用数字光处理(DLP)3D 打印技术制备酒石酸唑吡坦速释口服制剂的配方和特性研究。

Formulation and characterization of immediate-release oral dosage forms with zolpidem tartrate fabricated by digital light processing (DLP) 3D printing technique.

机构信息

Department of Pharmaceutical Technology and Cosmetology, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia.

Institute for Medicines and Medical Devices of Montenegro, Ivana Crnojevića 64a, 81000 Podgorica, Montenegro.

出版信息

Int J Pharm. 2022 Aug 25;624:122046. doi: 10.1016/j.ijpharm.2022.122046. Epub 2022 Jul 29.

Abstract

The introduction of three-dimensional (3D) printing in the pharmaceutical field has made great strides towards innovations in the way drugs are designed and manufactured. In this study, digital light processing (DLP) technique was used to fabricate oral dosage forms of different shapes with zolpidem tartrate (ZT), incorporated within its therapeutic range. Formulation factors, such as poly(ethylene glycol) diacrylate (PEGDA) and poly(ethylene glycol) 400 (PEG 400) ratio, as well as water content, were varied in combination with the surface area/volume (SA/V) ratio to achieve immediate drug release. Hypromellose (HPMC) was used as a stabilizing agent of photoreactive suspensions in an attempt to prevent drug sedimentation and subsequent variations in drug content uniformity. Oral dosage forms with doses in the range from 0.15 mg to 6.37 mg, showing very rapid and rapid drug dissolution, were successfully fabricated, confirming the potential of this technique in drug manufacturing with the ability to provide flexible dose adjustments and desirable release profiles by varying formulation factors and geometry of 3D models. DSC (differential scanning calorimetry), XRPD (X-ray powder diffraction) and scanning electron microscopy (SEM) showed that ZT remained in a crystalline form within printed dosage forms and no interactions were found between ZT and polymers.

摘要

三维(3D)打印技术在制药领域的引入,在药物设计和制造方式的创新方面取得了重大进展。在这项研究中,使用数字光处理(DLP)技术制造了不同形状的佐匹克隆酒石酸盐(ZT)口服剂型,其范围在治疗范围内。制剂因素,如聚乙二醇二丙烯酸酯(PEGDA)和聚乙二醇 400(PEG 400)的比例,以及含水量,与表面积/体积(SA/V)比相结合进行变化,以实现药物的立即释放。羟丙甲纤维素(HPMC)被用作光反应悬浮液的稳定剂,以试图防止药物沉淀和随后的药物含量均匀度变化。成功制造了剂量范围为 0.15mg 至 6.37mg 的口服剂型,显示出非常快速和快速的药物溶解,这证实了该技术在药物制造中的潜力,通过改变制剂因素和 3D 模型的几何形状,能够提供灵活的剂量调整和理想的释放曲线。差示扫描量热法(DSC)、X 射线粉末衍射(XRPD)和扫描电子显微镜(SEM)表明,ZT 在打印的剂型中仍然保持结晶形式,并且在 ZT 和聚合物之间没有发现相互作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验